NATCO PHARMA LTD. Fair Value
NATCOPHARM · Healthcare · Current price ₹945
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹650 | 17% ROE fading to 12% over ~10 yrs, on ₹515 book |
| Relative P/E | ₹2,401 | EPS × 30.3 peer-median P/E |
| Graham floor | ₹958 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is NATCO PHARMA LTD. undervalued?
DocStoX estimates the fair value of NATCO PHARMA LTD. at ₹1,191 per share, versus the current market price of ₹945. That puts the stock about +26.0% below our fair-value estimate, which we read as "Buy". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹650), Relative P/E (₹2,401), Graham floor (₹958). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹650 (bear) to ₹1,191 (base) to ₹2,401 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on NATCO PHARMA LTD.
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.